Loctek Ergonomic Technology Corp.'s (SZSE:300729) Intrinsic Value Is Potentially 56% Above Its Share Price
Loctek Ergonomic Technology Corp.'s (SZSE:300729) Intrinsic Value Is Potentially 56% Above Its Share Price
Key Insights
- The projected fair value for Loctek Ergonomic Technology is CN¥24.30 based on 2 Stage Free Cash Flow to Equity
- Current share price of CN¥15.54 suggests Loctek Ergonomic Technology is potentially 36% undervalued
- Analyst price target for 300729 is CN¥23.50 which is 3.3% below our fair value estimate
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Loctek Ergonomic Technology Corp. (SZSE:300729) as an investment opportunity by estimating the company's future cash flows and discounting them to their present value. Our analysis will employ the Discounted Cash Flow (DCF) model. Before you think you won't be able to understand it, just read on! It's actually much less complex than you'd imagine.
Remember though, that there are many ways to estimate a company's value, and a DCF is just one method. Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model.
Crunching The Numbers
We're using the 2-stage growth model, which simply means we take in account two stages of company's growth. In the initial period the company may have a higher growth rate and the second stage is usually assumed to have a stable growth rate. To begin with, we have to get estimates of the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.
A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, so we discount the value of these future cash flows to their estimated value in today's dollars:
10-year free cash flow (FCF) forecast
2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | |
Levered FCF (CN¥, Millions) | CN¥508.0m | CN¥520.0m | CN¥532.3m | CN¥545.6m | CN¥559.8m | CN¥574.9m | CN¥590.6m | CN¥606.9m | CN¥623.9m | CN¥641.4m |
Growth Rate Estimate Source | Analyst x1 | Analyst x1 | Est @ 2.36% | Est @ 2.51% | Est @ 2.61% | Est @ 2.68% | Est @ 2.73% | Est @ 2.77% | Est @ 2.79% | Est @ 2.81% |
Present Value (CN¥, Millions) Discounted @ 9.4% | CN¥464 | CN¥435 | CN¥407 | CN¥381 | CN¥357 | CN¥336 | CN¥315 | CN¥296 | CN¥278 | CN¥261 |
("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = CN¥3.5b
The second stage is also known as Terminal Value, this is the business's cash flow after the first stage. For a number of reasons a very conservative growth rate is used that cannot exceed that of a country's GDP growth. In this case we have used the 5-year average of the 10-year government bond yield (2.9%) to estimate future growth. In the same way as with the 10-year 'growth' period, we discount future cash flows to today's value, using a cost of equity of 9.4%.
Terminal Value (TV)= FCF2034 × (1 + g) ÷ (r – g) = CN¥641m× (1 + 2.9%) ÷ (9.4%– 2.9%) = CN¥10b
Present Value of Terminal Value (PVTV)= TV / (1 + r)10= CN¥10b÷ ( 1 + 9.4%)10= CN¥4.1b
The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is CN¥7.6b. In the final step we divide the equity value by the number of shares outstanding. Relative to the current share price of CN¥15.5, the company appears quite undervalued at a 36% discount to where the stock price trades currently. The assumptions in any calculation have a big impact on the valuation, so it is better to view this as a rough estimate, not precise down to the last cent.
Important Assumptions
We would point out that the most important inputs to a discounted cash flow are the discount rate and of course the actual cash flows. If you don't agree with these result, have a go at the calculation yourself and play with the assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Loctek Ergonomic Technology as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 9.4%, which is based on a levered beta of 1.313. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.
SWOT Analysis for Loctek Ergonomic Technology
- Debt is not viewed as a risk.
- Dividend is in the top 25% of dividend payers in the market.
- Dividend information for 300729.
- Earnings declined over the past year.
- Annual revenue is forecast to grow faster than the Chinese market.
- Good value based on P/E ratio and estimated fair value.
- Paying a dividend but company has no free cash flows.
- Annual earnings are forecast to grow slower than the Chinese market.
- See 300729's dividend history.
Next Steps:
Whilst important, the DCF calculation ideally won't be the sole piece of analysis you scrutinize for a company. It's not possible to obtain a foolproof valuation with a DCF model. Rather it should be seen as a guide to "what assumptions need to be true for this stock to be under/overvalued?" If a company grows at a different rate, or if its cost of equity or risk free rate changes sharply, the output can look very different. Can we work out why the company is trading at a discount to intrinsic value? For Loctek Ergonomic Technology, we've compiled three additional items you should look at:
- Risks: Case in point, we've spotted 3 warning signs for Loctek Ergonomic Technology you should be aware of, and 1 of them is concerning.
- Future Earnings: How does 300729's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
- Other High Quality Alternatives: Do you like a good all-rounder? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing!
PS. Simply Wall St updates its DCF calculation for every Chinese stock every day, so if you want to find the intrinsic value of any other stock just search here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.